Most Read Articles
2 days ago
Age and sex do not appear to influence outcomes after percutaneous coronary intervention (PCI) or coronary-artery bypass grafting (CABG) for left main coronary artery disease, reports a recent study.
20 Jun 2019
Untreated white coat hypertension (WCH), but not treated white coat effect (WCE), may increase the risk for cardiovascular events and all-cause mortality, suggest the results of a systematic review and meta-analysis. Out-of-office blood pressure (BP) monitoring is thus important in the diagnosis and management of hypertension.
06 Aug 2019
Risk factors for 1-year mortality in heart failure (HF) patients significantly differ between those with and without chronic kidney disease (CKD), especially with regard to the use of beta-blockers or diuretics at discharge, according to a study. This suggests that these patients may benefit from individualized therapies.
23 Jun 2019
Implementing the 2017 American College of Cardiology/American Heart Association (ACC/AHA) guideline over that of the 2018 European Society of Cardiology/European Society of Hypertension (ESC/ESH) will give rise to a substantial increase in the prevalence of hypertension, as well as the number of adults who should receive medication, according to a study.

Psoriasis drug may help fight coronary plaques

10 Feb 2019

Biologic therapies for severe psoriasis appear to help reduce noncalcified coronary plaques and improve plaque morphology, a recent study has shown.

Researchers conducted a prospective observational study including 121 psoriasis patients, of whom 89 received biologic treatments (mean age 49.1±12.2 years; 56 percent male) and 32 (mean age 51.2±12.0 years; 63 percent male) were treated with other agents. Participants tended to have low cardiovascular risk (median Framingham score, 3) with moderate-to-severe skin disease (median Psoriasis Area and Severity Index [PASI], 8.6).

After a year of follow-up, patients who were treated with biologic agents showed significant improvements in the PASI score (64-percent improvement, p<0.001), as well as a significant reduction in high-sensitivity C-reactive protein levels (p<0.001). No such changes were observed in the comparison group.

Moreover, a 5-percent decrease in total coronary plaque burden was observed in participants on biologic therapy (p=0.009), an effect primarily driven by a drop in the noncalcified plaque burden (p=0.005). No improvements in fibrous burden (p=0.71) were reported, though fibro-fatty (p=0.004) and necrotic (p=0.03) burdens decreased.

In comparison, those receiving nonbiologic interventions showed no significant 1-year change in total plaque burden (p=0.22), noncalcified plaque burden (p=0.17) and fibrous burden (p=0.22). There was also an increase in fibro-fatty burden (p=0.004).

Intergroup comparisons showed that the 1-year reduction in noncalcified plaque was significantly greater in patients treated with biologic agents (p=0.03) even after adjustments for cardiovascular risk factors.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Age and sex do not appear to influence outcomes after percutaneous coronary intervention (PCI) or coronary-artery bypass grafting (CABG) for left main coronary artery disease, reports a recent study.
20 Jun 2019
Untreated white coat hypertension (WCH), but not treated white coat effect (WCE), may increase the risk for cardiovascular events and all-cause mortality, suggest the results of a systematic review and meta-analysis. Out-of-office blood pressure (BP) monitoring is thus important in the diagnosis and management of hypertension.
06 Aug 2019
Risk factors for 1-year mortality in heart failure (HF) patients significantly differ between those with and without chronic kidney disease (CKD), especially with regard to the use of beta-blockers or diuretics at discharge, according to a study. This suggests that these patients may benefit from individualized therapies.
23 Jun 2019
Implementing the 2017 American College of Cardiology/American Heart Association (ACC/AHA) guideline over that of the 2018 European Society of Cardiology/European Society of Hypertension (ESC/ESH) will give rise to a substantial increase in the prevalence of hypertension, as well as the number of adults who should receive medication, according to a study.